Vivimed Labs Limited (VIVIMEDLAB) AI Stock Analysis

Vivimed Labs Limited

(NSE:VIVIMEDLAB)

Select Model

Rating:45Neutral

Price Target:INR 6.00▼(-1.80% Downside)

Action:upgraded

Date:08/27/26

The score is held down primarily by very weak financial performance, including persistent losses, deteriorating margins, and a highly stressed balance sheet with negative equity and high debt. Technicals provide only partial support due to strong short-term momentum, but overbought signals and a weaker long-term trend limit the benefit. Valuation remains challenged because the company is loss-making (negative P/E) and lacks dividend yield support.

Positive Factors

Specialty pharmaceutical capabilitiesVivimed’s focus on APIs, intermediates, niche molecules and contract manufacturing provides specialized routes to serve pharmaceutical customers. Chemistry capabilities and participation in regulated and semi-regulated markets can support durable relevance beyond a single product cycle.

Negative Factors

Persistent revenue contractionRepeated revenue declines indicate that Vivimed has not yet established a durable growth trajectory. Continued contraction can reduce operating leverage, weaken customer and product scale, and make it harder for fixed costs to be absorbed over the next several quarters.

Vivimed Labs Limited (VIVIMEDLAB) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 458.51M
Dividend Yield: ―
Average Volume (3M): 16.57K
Price to Earnings (P/E): -0.3
Beta (1Y): 0.43
Revenue Growth: -39.80%
EPS Growth: -452.04%
Country: India
Employees: 586
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Vivimed Labs Limited Business Overview & Revenue Model

Company Description

Established in 1988 and headquartered in Hyderabad, India, Vivimed Labs Limited, along with its associated entities, is an international manufacturer and supplier of diverse products, including active pharmaceutical ingredients (APIs), finished drug...

Vivimed Labs Limited Financial Statement Overview

Summary

Financials are severely weakened: revenues have been declining for multiple years, operating profit and net income are negative across all years shown, and 2026 margins deteriorated sharply (gross profit turning negative). The balance sheet is highly stressed with negative equity (2024–2026) alongside high debt, limiting financial flexibility. Cash flow improved in 2026 with positive operating and free cash flow, but history shows high volatility, which reduces confidence.

Income Statement

12Very Negative

Balance Sheet

9Very Negative

Cash Flow

28Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	699.89M	699.89M	1.16B	1.49B	1.87B	2.37B
Gross Profit	-335.58M	-547.76M	77.98M	705.71M	-928.65M	838.04M
EBITDA	-1.46B	-1.46B	-86.77M	-246.69M	-1.86B	-67.91M
Net Income	-1.76B	-1.76B	-319.61M	-454.46M	-3.29B	-676.50M
Balance Sheet
Total Assets	7.53B	7.53B	9.21B	9.51B	9.88B	12.66B
Cash, Cash Equivalents and Short-Term Investments	13.56M	13.56M	7.08M	717.79M	37.62M	71.84M
Total Debt	3.97B	3.97B	3.76B	3.79B	3.81B	2.78B
Total Liabilities	9.64B	9.64B	9.56B	9.56B	9.49B	9.02B
Stockholders Equity	-2.11B	-2.11B	-351.69M	-54.61M	394.23M	3.64B
Cash Flow
Free Cash Flow	67.56M	67.56M	-86.28M	-260.30M	303.54M	-6.75B
Operating Cash Flow	77.03M	77.03M	-40.97M	-239.91M	138.12M	-6.58B
Investing Cash Flow	-9.47M	-9.47M	-45.31M	282.88M	-49.68M	5.23B
Financing Cash Flow	-61.07M	-61.07M	73.10M	-60.32M	-162.44M	-103.80M

Vivimed Labs Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price6.11

Price Trends

50DMA6.23Negative

100DMA5.86Positive

200DMA6.51Negative

Market Momentum

MACD0.01Positive

RSI46.87Neutral

STOCH20.81Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIVIMEDLAB, the sentiment is Negative. The current price of 6.11 is below the 20-day moving average (MA) of 6.36, below the 50-day MA of 6.23, and below the 200-day MA of 6.51, indicating a bearish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 46.87 is Neutral, neither overbought nor oversold. The STOCH value of 20.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VIVIMEDLAB.

Vivimed Labs Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:VIVIMEDLAB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:GRANULES	64Neutral	INR 208.04B	31.03	―	0.21%	24.83%	36.88%
IN:NEULANDLAB	64Neutral	INR 252.76B	50.78	―	0.17%	78.33%	182.61%
IN:HIKAL	61Neutral	INR 26.01B	-77.22	―	0.28%	-5.37%	-153.40%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:LAURUSLABS	54Neutral	INR 1.29T	96.96	―	0.08%	23.03%	95.69%
IN:SOLARA	51Neutral	INR 30.43B	81.94	―	―	27.30%	456.80%
IN:VIVIMEDLAB	45Neutral	INR 506.60M	-0.26	―	―	-39.80%	-452.04%

* General Sector Average

Performance Comparison

IN:VIVIMEDLAB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:VIVIMEDLAB	Vivimed Labs Limited	6.11	1.21	24.69%
IN:GRANULES	Granules India Limited	839.55	267.34	46.72%
IN:HIKAL	Hikal Limited	210.95	-32.96	-13.51%
IN:LAURUSLABS	Laurus Labs Ltd.	2392.00	1417.82	145.54%
IN:NEULANDLAB	Neuland Laboratories Ltd.	19701.10	2581.84	15.08%
IN:SOLARA	Solara Active Pharma Sciences Ltd.	633.05	1.10	0.17%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 27, 2026

Vivimed Labs Limited AI Stock Analysis